{"id":46375,"date":"2022-07-20T15:02:05","date_gmt":"2022-07-20T13:02:05","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\/"},"modified":"2022-07-20T15:02:05","modified_gmt":"2022-07-20T13:02:05","slug":"guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\/","title":{"rendered":"Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva\u00ae Advanced Cervical Scan"},"content":{"rendered":"
\n

PEACHTREE CORNERS, Ga.–(BUSINESS WIRE)–#HPV<\/a>–Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, announced that it has obtained Institutional Review Board (IRB) approval to initiate its clinical trial aimed at obtaining FDA approval for the Company\u2019s flagship product, the LuViva Advanced Cervical Scan.\n<\/p>\n

<\/a><\/p>\n

\nThe study protocol has been approved by WCG IRB, a leader in quality ethical review with over 50 years of experience and their approval is accepted by multiple clinical sites including the two key centers that have agreed to participate in the LuViva study. Both of these centers have enough patient volume to provide the number of patients required by FDA, projected to be up to approximately 400 women. The study is expected to start enrolling patients in about 30 to 60 days.\n<\/p>\n

\nLuViva is already approved for sale in the European Union under the CE Mark and currently is undergoing clinical trials in China for National Medical Products Administration approval, China\u2019s equivalent of the U.S FDA.\n<\/p>\n

\n\u201cMultiple COVID-19 surges have had a significant impact on the start of our study, as it has for most non-COVID related products,\u201d said Gene Cartwright, CEO of Guided Therapeutics. \u201cWe are extremely gratified to have received a blanket IRB approval from WCG IRB that allows us to begin our study at prestigious medical institutions that are excited to be working with LuViva.\u201d\n<\/p>\n

\nAbout Guided Therapeutics<\/b>\n<\/p>\n

\nGuided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company\u2019s first product is the LuViva\u00ae Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: www.guidedinc.com<\/a>.\n<\/p>\n

\nThe Guided Therapeutics LuViva\u00ae <\/sup>Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and “Early detection, better outcomes” are registered trademarks owned by Guided Therapeutics, Inc.<\/i>\n<\/p>\n

\nForward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics\u2019 actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading \u201cRisk Factors\u201d in Guided Therapeutics\u2019 reports filed with the SEC, including Guided Therapeutics\u2019 Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and subsequent filings.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMark Faupel
\n
Guided Therapeutics
\n
770-242-8723\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

PEACHTREE CORNERS, Ga.–(BUSINESS WIRE)–#HPV–Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, announced that it has obtained Institutional Review Board (IRB) approval to initiate its clinical trial aimed at obtaining FDA approval for the Company\u2019s flagship product, the LuViva Advanced … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46375","6":"format-standard","7":"category-industry"},"yoast_head":"\nGuided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva\u00ae Advanced Cervical Scan - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva\u00ae Advanced Cervical Scan - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PEACHTREE CORNERS, Ga.–(BUSINESS WIRE)–#HPV–Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, announced that it has obtained Institutional Review Board (IRB) approval to initiate its clinical trial aimed at obtaining FDA approval for the Company\u2019s flagship product, the LuViva Advanced ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-20T13:02:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220720005063\/en\/1517908\/21\/GTI_logo_2021.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva\u00ae Advanced Cervical Scan\",\"datePublished\":\"2022-07-20T13:02:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\\\/\"},\"wordCount\":607,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220720005063\\\/en\\\/1517908\\\/21\\\/GTI_logo_2021.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\\\/\",\"name\":\"Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva\u00ae Advanced Cervical Scan - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220720005063\\\/en\\\/1517908\\\/21\\\/GTI_logo_2021.jpg\",\"datePublished\":\"2022-07-20T13:02:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220720005063\\\/en\\\/1517908\\\/21\\\/GTI_logo_2021.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220720005063\\\/en\\\/1517908\\\/21\\\/GTI_logo_2021.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva\u00ae Advanced Cervical Scan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva\u00ae Advanced Cervical Scan - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\/","og_locale":"en_US","og_type":"article","og_title":"Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva\u00ae Advanced Cervical Scan - Pharma Trend","og_description":"PEACHTREE CORNERS, Ga.–(BUSINESS WIRE)–#HPV–Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, announced that it has obtained Institutional Review Board (IRB) approval to initiate its clinical trial aimed at obtaining FDA approval for the Company\u2019s flagship product, the LuViva Advanced ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-20T13:02:05+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220720005063\/en\/1517908\/21\/GTI_logo_2021.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva\u00ae Advanced Cervical Scan","datePublished":"2022-07-20T13:02:05+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\/"},"wordCount":607,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220720005063\/en\/1517908\/21\/GTI_logo_2021.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\/","url":"https:\/\/pharma-trend.com\/en\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\/","name":"Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva\u00ae Advanced Cervical Scan - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220720005063\/en\/1517908\/21\/GTI_logo_2021.jpg","datePublished":"2022-07-20T13:02:05+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220720005063\/en\/1517908\/21\/GTI_logo_2021.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220720005063\/en\/1517908\/21\/GTI_logo_2021.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/guided-therapeutics-receives-institutional-review-board-approval-to-start-clinical-study-for-fda-approval-of-the-luviva-advanced-cervical-scan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva\u00ae Advanced Cervical Scan"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46375","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46375"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46375\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46375"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46375"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46375"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}